Zynerba Pharma Balance Sheet - Annual (NASDAQ:ZYNE)

Add to My Stocks
$9.42 $0.75 (7.37%) ZYNE stock closing price Mar 16, 2018 (Closing)

A thorough fundamental analysis involves using data from Zynerba Pharma balance sheet, apart from other financial statements, to value the business. Financial strength can be guaged by performing Zynerba Pharma stock analysis and by analyzing the balance sheet. Annual results are typically accompanied with the company releasing financial statements. The Zynerba Pharma balance sheet for 2016 shows total assets of $36.55M. The company has a asset turnover ratio of 0. Also see: Zynerba Pharma revenue and Zynerba Pharma operating cash flow for the same year.

View latest 10 year balance sheet data to check Zynerba Pharma financial performance.
show more
Fiscal year is Jan - Dec2016201520142013
Marketable Securities----
Raw Materials----
Work In Progress----
Finished Goods----
Notes Receivable----
Other Current Assets1.83M1.9M2.26M-
Total Current Assets
Property Plant & Equipment----
Accumulated Depreciation----
Net Property Plant & Equipment
Investment & Advances----
Other Non-Current Assets----
Deferred Charges----
Deposits & Other Assets---1.12M
Total Assets
Notes Payable----
Accounts Payable1.84M---
Current Portion Long-Term Debt----
Current Portion Capital Leases----
Accrued Expenses4.28M2.27M1.71M-
Income Taxes Payable----
Other Current Liabilities--1.12M1.07M
Total Current Liabilities
Deferred Taxes/Income---1.12M
Convertible Debt----
Long-Term Debt----
Non-Current Capital Leases----
Other Long-Term Liabilities----
Total Liabilities
Minority Interest----
Preferred Stock--16.52M3.16M
Common Stock Net----
Capital Surplus75.54M62.27M1.97M-
Retained Earnings-45.96M-22.58M-10.02M-4.35M
Treasury Stock----
Other Liabilities----
Shareholders Equity29.58M39.7M8.47M-1.19M
Total Liabilities & Shareholders Equity36.55M43.64M11.61M1.86M
All figures in USD. M: Millions of USD, B: Billions of USD.

Click here to view our Pfizer financial analysis

Apart from balance sheet items, an investor would do well to keep track of the Zynerba Pharma stock price by looking at Zynerba Pharma historical stock prices. One can compare PE with industry average by looking at the Zynerba Pharma PE ratio chart. The common balance sheet items are:

  • Assets: An asset is a resource that a corporation like Zynerba Pharma owns and has monetary significance. ZYNE assets decreased from $43.64M in 2015 to $36.55M in 2016. Assets can be of two types: fixed assets like real estate, plant and machinery; and current assets which includes cash, accounts receivable etc. Tech stocks typically don't have too many assets.
  • Liabilities or obligations comprise of current liabilities that include short term loans, amounts payable to suppliers, or any other outstanding payments including long term liabilities that take into account long term loans for funding large projects. The total liabilities for Zynerba Pharma is $6.96M. Shareholders' equity comes under liabilities as it is money the company owes the holders of ZYNE stock.

Zynerba Pharma Balance Sheet - Key Ratios

Current ratio
Debt to equity ratio
Asset turnover ratio
Receivables turnover